LONG-TERM EFFECTS OF TAMOXIFEN - BIOLOGICAL EFFECTS OF TAMOXIFEN WORKING PARTY

被引:55
作者
CUZICK, J
ALLEN, D
BAUM, M
BARRETT, J
CLARK, G
KAKKAR, V
MELISSARI, E
MONIZ, C
MOORE, J
PARSONS, V
PEMBERTON, K
PITT, P
RICHMOND, W
HOUGHTON, J
RILEY, D
机构
关键词
D O I
10.1016/0959-8049(93)90568-Z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A total of 153 breast cancer patients who participated in two trials of adjuvant tamoxifen and who had not recurred were recruited into a study of the long term effects of tamoxifen. There were 60 controls (no tamoxifen), 73 ex-users (mostly for 2 years) and 20 current users (median treatment duration 72 months) and the median follow-up time was 7 years. A wide ranging study of lipids, hormones, bone density and haemostasis was undertaken. When compared with controls, current users had lower cholesterol levels (especially low density cholesterol), and increased triglyceride levels. Thyroid hormones were higher and sex hormone binding globulin was almost doubled. Bone density was non-significantly higher, clotting times were slightly shorter and fibrinogen and antithrombin III levels were reduced. However few of these changes persisted in ex-users, suggesting that most of the biological effects of treatment are reversible on cessation of treatment. This is reassuring for potentially negative side-effects, but also indicates that potentially positive 'side-effects' such as cholesterol lowering only occur while on active treatment.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 27 条
[1]   EFFECTS OF TAMOXIFEN TREATMENT ON PLASMA-LIPIDS AND LIPOPROTEIN LIPID-COMPOSITION [J].
BAGDADE, JD ;
WOLTER, J ;
SUBBAIAH, PV ;
RYAN, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (04) :1132-1135
[2]   ADJUVANT TAMOXIFEN IN PRIMARY BREAST-CANCER - INFLUENCE ON PLASMA-LIPIDS AND ANTITHROMBIN-III LEVELS [J].
BERTELLI, G ;
PRONZATO, P ;
AMOROSO, D ;
CUSIMANO, MP ;
CONTE, PF ;
MONTAGNA, G ;
BERTOLINI, S ;
ROSSO, R .
BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (03) :307-310
[3]   TAMOXIFEN, SERUM-LIPOPROTEINS AND CARDIOVASCULAR RISK [J].
BRUNING, PF ;
BONFRER, JMG ;
HART, AAM ;
DEJONGBAKKER, M ;
LINDERS, D ;
VANLOON, J ;
NOOYEN, WJ .
BRITISH JOURNAL OF CANCER, 1988, 58 (04) :497-499
[4]   EFFECT OF TAMOXIFEN ON ESTROGEN BINDING, LIPID AND LIPOPROTEIN CONCENTRATIONS AND BLOOD-CLOTTING PARAMETERS IN PREMENOPAUSAL WOMEN WITH BREAST PAIN [J].
CALEFFI, M ;
FENTIMAN, IS ;
CLARK, GM ;
WANG, DY ;
NEEDHAM, J ;
CLARK, K ;
LAVILLE, A ;
LEWIS, B .
JOURNAL OF ENDOCRINOLOGY, 1988, 119 (02) :335-339
[5]  
CUZICK J, 1986, LANCET, V1, P83
[6]  
CUZICK J, 1985, LANCET, V1, P282
[7]  
EBCTC Group, 1992, LANCET, V339, P1
[8]   BONE-MINERAL CONTENT OF WOMEN RECEIVING TAMOXIFEN FOR MASTALGIA [J].
FENTIMAN, IS ;
CALEFFI, M ;
RODIN, A ;
MURBY, B ;
FOGELMAN, I .
BRITISH JOURNAL OF CANCER, 1989, 60 (02) :262-264
[9]   ESTROGEN-LIKE EFFECTS OF TAMOXIFEN ON THE CONCENTRATION OF PROTEINS IN PLASMA [J].
FEX, G ;
ADIELSSON, G ;
MATTSON, W .
ACTA ENDOCRINOLOGICA, 1981, 97 (01) :109-113
[10]  
Friedwald W. J., 1972, CLIN CHEM, V18, P449